Houston tech company launches $40M fund to invest in early-stage startups

money moves

A Houston software company has announced its new venture fund. Photo via Getty Images

A Houston company that recently launched an innovation studio to support startups has now announced that they are launching a new fund to take startup support to the next level.

Houston-based Softeq Development Corporation, a global full-stack development company, launched The Softeq Venture Fund, a $40 million venture fund to invest in seed and series A startup rounds. According to a news release, more than half the fund will be deployed to power the Softeq Venture Studio, Softeq's recently launched accelerator program.

“For generations, the state of Texas has been home to world-renowned tech companies who have greatly contributed to our regional success. As a local entrepreneur, advisor, and angel investor, it’s been my dream for many years to create a venture fund benefiting startups," says Christopher A. Howard, founder and CEO of Softeq, in the release. "I am proud to increase our support of the state’s early-stage tech community. Our investment fund is designed to attract tech visionaries from both inside and outside the state and grow innovative concepts in Houston."

Jumana Capital, a single-family office also based in Houston and founded in 2018, has made a "sizable investment" in the fund, per the release.

“The Softeq team has successfully engineered, developed, and launched technology solutions for enterprise and early-stage companies for 25 years. In partnership with Softeq, we are thrilled to play a role in the creation of their new fund and to support the entrepreneurs that come to Houston to develop cutting-edge technologies and build businesses,” says Chris Martin, managing director at Jumana Capital, in the release.

While the fund will mostly go into investing in and supporting studio companies, Softeq will also tap into the fund to "invest opportunistically."

In October, the company announced the six startups that make up the studio's inaugural cohort. The purpose of the studio was to identify startups with scalable solutions but that need guidance and support from Softeq and its network.

"Historically, most tech startups had a founder with development skills. However, we're now seeing more and more business people, doctors, and other professionals start companies, and they need a strong engineering partner to develop their products," Howard says in an October news release. "We take it several steps further with the Venture Studio providing technology business consulting, development services, and much-needed cash. We're a vested partner, so we also help secure follow-on funding for continued growth."

Applications are open for the spring 2022 cohort. More information and applications are available online.

Christopher A. Howard is the founder and CEO of Softeq. Photo courtesy of Softeq

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Tom Hanks touches down at Space Center Houston for lunar film premiere

To The Moon

The Artemis Exhibit at Space Center Houston shimmered with star power as nearly 500 insiders gathered for an out-of-this-world affair celebrating the premiere of The Moonwalkers: A Journey with Tom Hanks. The immersive cinematic experience, narrated and co-written by Oscar-winning actor Tom Hanks, offers guests a front-row seat to the triumphs of past lunar missions and a look ahead to NASA’s Artemis era.

The VIP reception brought a celestial twist to the traditional cocktail hour. Guests were served shrimp and oysters, along with potato croquettes paired with peach gastrique, a playful nod to the first vegetable grown in space and the first fruit consumed on the Moon. Espresso martinis featuring Hanks’ coffee brand, Hanx, were shaken and served.

Inside the newly renovated Space Center Theater, a 270-degree projection mapping spectacle brought The Moonwalkers to life. The film weaves rare astronaut interviews with behind-the-scenes glimpses into the upcoming Artemis missions.

Following the screening, a panel discussion brought the experience back to Earth. William T. Harris, Space Center Houston president and CEO, moderated a conversation with Tom Hanks, Apollo 16 moonwalker Charlie Duke, and Artemis II astronauts Victor Glover, Christina Koch, and Reid Wiseman. Together, they explored the film’s themes and what lies ahead as humanity returns to the Moon.

The Moonwalkers: A Journey with Tom Hanks is now on view at Space Center Houston. The immersive show is included in the general admission price. It runs 50 minutes and showings begin on the half hour, starting at 10:30 am.

---

A version of this story originally appeared on our sister site, CultureMap.com.

Houston space org to launch experiments aboard first mission into polar orbit

all aboard

Houston's Translational Research Institute for Space Health, or TRISH, will send its latest experiments into space aboard the Fram2 mission, the first all-civilian human spaceflight mission to launch over the Earth’s polar regions.

Fram2, operated by SpaceX, is targeting to launch Monday, March 31, at NASA’s Kennedy Space Center in Florida. The crew of four is expected to spend several days in polar orbit aboard the SpaceX Dragon spacecraft in low Earth orbit. TRISH’s research projects are among 22 experiments that the crew will conduct onboard.

The crew's findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and will be used to help enhance human health and performance during spaceflight missions, including missions to the moon and Mars, according to a release from TRISH.

“The valuable space health data that will be captured during Fram2 will advance our understanding of how humans respond and adapt to the stressors of space,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor in Baylor’s Center for Space Medicine, said in the release. “Thanks to the continued interest in furthering space health by commercial space crews, each human health research project sent into orbit brings us closer to improving crew member well-being aboard future spaceflight missions.”

The six TRISH projects on Fram2 include:

  • Cognitive and Physiologic Responses in Commercial Space Crew on Short-Duration Missions, led by Dr. Mathias Basner at the University of Pennsylvania Perelman School of Medicine. The crew will wear a Garmin smartwatch and a BioIntelliSense BioButton® medical grade device to track cognitive performance, including memory, spatial orientation, and attention before, during, and after the mission.
  • Otolith and Posture Evaluation II, led by Mark Shelhamer at Johns Hopkins University. The experiment will look at how astronauts’ eyes sense and respond to motion before and after spaceflight to better understand motion sickness in space.
  • REM and CAD Radiation Monitoring for Private Astronaut Spaceflight, led by Stuart George at NASA Johnson Space Center. This experiment will test space radiation exposure over the Earth’s north and south poles and how this impacts crew members.
  • Space Omics + BioBank, led by Richard Gibbs and Harsha Doddapaneni at Baylor College of Medicine. The experiment will use Baylor’s Human Genome Sequencing Center's Genomic Evaluation of Space Travel and Research program to gain insights from pre-flight and post-flight samples from astronauts.
  • Standardized research questionnaires, led by TRISH. The test asks a set of standardized research questionnaires for the crew to collect data on their sleep, personality, health history, team dynamics and immune-related symptoms.
  • Sensorimotor adaptation, led by TRISH. The project collects data before and after flight to understand sensorimotor abilities, change and recovery time to inform future missions to the moon.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, including Blue Origin's New Shepard rocket last November and Axiom Space's Ax-3 mission to the International Space Station last January.

Houston lab develops AI tool to improve neurodevelopmental diagnoses

developing news

One of the hardest parts of any medical condition is waiting for answers. Speeding up an accurate diagnosis can be a doctor’s greatest mercy to a family. A team at Baylor College of Medicine has created technology that may do exactly that.

Led by Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, the scientists have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

According to its website, Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa said in a news release.

Typically, scientists must sequence the genes of many people with a diagnosis, as well as people not affected by the disorder, to find new genes associated with a particular disease or disorder. That takes time, money, and a little bit of luck. AI minimizes the need for all three, explains Dhindsa: “We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders.”

The models, made using patterns expressed at the single-cell level, are augmented with north of 300 additional biological features, including data on how intolerant genes are to mutations, whether they interact with other known disease-associated genes, and their functional roles in different biological pathways.

Dhindsa says that these models have exceptionally high predictive value.

“Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone,” he said in the release. “Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower-ranking genes.”

That means that the models may actually validate genes that haven’t yet been proven to be involved in neurodevelopmental conditions. Gene discovery done with the help of AI could possibly become the new normal for families seeking answers beyond umbrella terms like “autism spectrum disorder.”

“We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility,” Dhindsa added.

View All Listings